A new technology and a new choice is here. Human derived placental grafts are routinely used for treatment of surgical and chronic wounds. However they are limited by supply availability, graft variability, cellular debris and DNA remnants, and high costs with limited sizes. Panelists will discuss the advantages and clinical applications of the first and only placental medical device (cleared by the FDA to address chronic, burn and complex surgical wounds) designed to solve this problem.
At the end of this session the learner will be able to: a. Understand how a placental medical device ECM, composed of highly controlled and monitored source material, helps produce a reliable and consistent ECM while addressing inherent graft variability of human donated placenta grafts. b. Understand the role of M1 and M2 macrophages in wound healing and how a well decellularized ECM can create a wound environment suitable for a greater healing response. c. Recognize the inherent benefits of placental derived ECM and the limitations associated with human placental grafts. d. Identify the surgical and chronic wound applications of the only FDA cleared placental medical device for wound management.
Sponsor: Triad Life Sciences
***** Innovation Theaters are informational sessions designed to complement the educational experience by further enhancing knowledge and confidence of disease-states or products. Innovation Theaters are non-accredited and no CME/CE credits are offered at these programs.
This session is complimentary for registered SAWC Spring attendees; however, additional registration is required. To add this session to your existing registration: Visit the registration page / select “Get Log in Link”/ “Edit Registration”/navigate through the registration until the “Additional Products” page/add the session to your registration. For questions, please contact registration@hmpglobal.com. Space is limited and available on a first-come, first-served basis. *****